A slight increase in melanoma risk was observed among sodium-glucose co-transporter-2 (SGLT-2) inhibitor users in the regular reports. However, the association remains uncertain. To address this issue, we performed a systematic search of electronic databases up to May 2, 2018
| INTRODUCTION
Sodium-glucose co-transporter-2 (SGLT-2) inhibitors are a novel class of antidiabetic drugs for the treatment of type 2 diabetes (T2D). 1 They lower blood glucose by inhibiting the reabsorption of glucose in the kidney. Given their additional benefits to the cardiovascular and renal systems, 2-5 more and more patients will be prescribed this class of medication. However, some evidence has indicated that SGLT-2 inhibitors may lead to serious adverse events (e.g. diabetic ketoacidosis
and below-knee lower extremity amputation). 6, 7 Furthermore, a slightly elevated risk of melanoma associated with empagliflozin use raises regulatory concerns. 8, 9 Given the rarity of melanoma cases in most randomized controlled trials (RCTs), such safety issues are difficult to address based on any individual short-term trial. Therefore, we conducted this meta-analysis of RCTs to comprehensively synthesize the evidence and maximize statistical power to detect any association between SGLT-2 inhibitors and risk of skin cancer, including melanoma and non-melanoma skin cancer (NMSC) among patients with T2D.
| METHODS

| Search strategy and study selection
PubMed, Embase, Cochrane Central Register of Controlled Trials (CENTRAL), and ClinicalTrials.gov were searched from inception to May 2, 2018 using relevant search terms without language restrictions (Table S1 in File S1). The reference lists of included studies, review articles and meta-analyses were checked to find additional eligible trials.
We included eligible trials that fulfilled the following criteria:
(1) published and unpublished RCTs; (2) adult patients with T2D; 
| Data extraction and risk of bias assessment
Two reviewers independently selected the potential trials, extracted data, and assessed the risk of bias of included trials. Any disagreements were resolved by consensus. We extracted the baseline demographic data, type of SGLT-2 inhibitor, type of control, background therapy, trial duration, and outcomes of interest. The data from the trial with the longest follow-up period were used in cases where various follow-up periods were reported. For a three-arm trial comparing 14 Bailey et al. 15 Barnett et al. 16 Haring et al. 17 Ridderstrale et al. 18 Zinman et al. 3 Grunberger et al. 19 Nauck et al. 20 Häring et al. 21 Roden et al. 22 Jabbour et al. 23 Kashiwagi et al. 24 Kovacs et al. 25 Leiter et al. 26 Bode et al. 27 Cefalu et al. 28 Lewin et al. 29 and DeFronzo et al. 30 NCT01649297 31 Yang et al. 32 Softeland et al. 33 Subtotal (I-squared = 0.0%, p = 0.620)
[in Non-melanoma skin cancer] Nauck et al. 20 Bailey et al. 15 Barnett et al. 16 Haring et al. 17 Jabbour et al. 23 Kovacs et al. 25 Leiter et al. 26 Ridderstrale et al. 18 Bode et al. 27 Cefalu et al. 28 Lewin et al. 29 and DeFronzo et al. 30 NCT01649297 31 Yang et al. 32 Zinman et al. 3 Softeland et al. 33 Grunberger et al. 19 Ferrannini et al. 14 Haring et al. 21 Roden et al. 22 Kashiwagi et al. 24 Subtotal (I-squared = 0.0%, p = 0.613) FIGURE 1 Meta-analysis of the association between SGLT-2 inhibitors and risk of melanoma and non-melanoma skin cancer in patients with type 2 diabetes Abbreviations: CI, confidence interval; Het, heterogeneity; SGLT-2 inhibitor, sodium-glucose co-transporter-2 inhibitor; S/C, SGLT-2 inhibitors group/control group; NA, not applicable.
a P-value for potential effect modification by each stratified factor on the pooled effect size estimate based on meta-regression models.
b P-value for interactions assessed with Cochran's Q-test.
interactions by these prespecified factors, P values for interactions were provided based on Cochran's Q test for assessing differences between the subgroups stratified by each factor, respectively. Further, meta-regression including each stratified factor as an independent variable (on a dichotomous scale) was also performed to investigate if the heterogeneity changed significantly between the subgroups stratified by that factor mentioned above. 13 Potential publication bias was assessed using both funnel plot and Egger's test. All statistical analyses were performed with STATA version 14 (College station, TX). A P value <0.05 was considered as statistically significant.
| RESULTS
Among the 3628 citations retrieved from the aforementioned electronic databases, 21 eligible RCTs involving 20 308 patients (median: 690; range: 332-7020 individuals) were included in this meta-analysis ( Figure S1 in File S1). 3, [14] [15] [16] [17] [18] [19] [20] [21] [22] [23] [24] [25] [26] [27] [28] [29] [30] [31] [32] [33] The characteristics and risk of bias of the studies included are presented in Table S2 and Figure S2 in File S1, respectively. The incidence of skin cancers was reported in only three articles and the others were extracted from www.clinicaltrials.gov. (Table 1 ).
In terms of NMSC risk, no significant association with SGLT-2 inhibitors was observed when all trials were combined (Peto OR, 0.70; 95% CI, 0.47-1.07), with event rates of 0.4% in the SGLT-2 inhibitor group and 0.6% in the control group (Figure 1) . When exploring the source of heterogeneity, the risk did not differ by the type of SGLT-2 inhibitor, type of control, or mean or median ages of patients (Table 1) . However, a significantly decreased risk of NMSC associated with SGLT-2 inhibitors was observed among trials with duration <52 weeks (Peto OR, 0.12; 95% CI, 0.02-0.59), but not among those ≥52 weeks (Peto OR, 0.80; 95% CI, 0.52-1.23) (P for interaction <0.05) ( Table 1) .
We observed zero, low and moderate degree of between-study heterogeneity in the analyses, with I 2 ranging from 0% to 56.4% (Table 1) . There was no evidence of publication bias based on Egger's test (P = 0.83 for melanoma, and P = 0.54 for NMSC) and funnel plot ( Figure S3 in File S1).
| DISCUSSION
The present meta-analysis showed that SGLT-2 inhibitors were not significantly associated with increased risk of melanoma among the patients with T2D. However, we cannot rule out the potential for harm. A non-significant decrease in risk of NMSC associated with SGLT-2 inhibitors was observed, while a significantly decreased risk was detected among trials with duration <52 weeks. There was zero, low and moderate heterogeneity in the meta-analyses. We acknowledge that our study had several limitations. First, our estimates may be subject to reporting bias because skin cancers were not specified end points in these trials which would result in less reports of skin cancers. In addition, only trials reporting the outcomes of skin cancer were considered in this meta-analysis. Second, our results should be interpreted with caution because of the small number of skin cancer cases and the short-term follow-up of included trials (median: 52 weeks). Our findings, especially in subgroup analyses, need to be further assessed by future long-term studies. Notably, no prospective observational study has examined the association of SGLT-2 inhibitors and risk of skin cancer yet. Therefore, we could not conduct the meta-analysis based on observational data.
In conclusion, current evidence from randomized trials did not find a significantly increased risk of skin cancer among patients taking SGLT-2 inhibitors. However, the potential melanoma risk by SGLT-2
inhibitors cannot be ruled out and should be further monitored in future large prospective observational studies and post-marketing surveillance.
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